

# FINEVIN™

(azelaic acid cream) 20%

For Dermatologic Use Only – Not for Ophthalmic Use

## Rx only

### DESCRIPTION

FINEVIN™ (azelaic acid cream) 20% contains azelaic acid, a naturally occurring saturated dicarboxylic acid.

Structural Formula:  $\text{HOOC}-(\text{CH}_2)_7-\text{COOH}$

Chemical Name: 1,7-heptanedecarboxylic acid

Empirical Formula:  $\text{C}_{16}\text{H}_{32}\text{O}_4$

Molecular Weight: 188.22

Active ingredient: Each gram of Finevin™ contains azelaic acid.....0.2 gm (20% w/w).

Inactive Ingredients: cetearyl octanoate, glycerin, glyceryl stearate and cetearyl alcohol and cetyl palmitate and cocoglycerides, PEG-5 glyceryl stearate, propylene glycol and purified water. Benzoic acid is present as a preservative.

### CLINICAL PHARMACOLOGY

The exact mechanism of action of azelaic acid is not known. The following *in vitro* data are available, but their clinical significance is unknown. Azelaic acid has been shown to possess antimicrobial activity against *Propionibacterium acnes* and *Staphylococcus epidermidis*. The antimicrobial action may be attributable to inhibition of microbial cellular protein synthesis.

A normalization of keratinization leading to an anticomedonal effect of azelaic acid may also contribute to its clinical activity. Electron microscopic and immunohistochemical evaluation of skin biopsies from human subjects treated with FINEVIN™ demonstrated a reduction in the thickness of the stratum corneum, a reduction in number and size of keratohyalin granules, and a reduction in the amount and distribution of filaggrin (protein component of keratohyalin) in epidermal layers. This is suggestive of the ability to decrease microcomedo formation.

**Pharmacokinetics:** Following a single application of FINEVIN™ to human skin *in vitro*, azelaic acid penetrates into the stratum corneum (approximately 3 to 5% of the applied dose) and other viable skin layers (up to 10% of the dose is found in the epidermis and dermis). Negligible cutaneous metabolism occurs after topical application. Approximately 4% of the topically applied azelaic acid is systemically absorbed. Azelaic acid is mainly excreted unchanged in the urine but undergoes some  $\beta$ -oxidation to shorter chain dicarboxylic acids. The observed half-lives in healthy subjects are approximately 45 minutes after oral dosing and 12 hours after topical dosing, indicating percutaneous absorption rate-limited kinetics.

Azelaic acid is a dietary constituent (whole grain cereals and animal products), and can be formed endogenously from longer-chain dicarboxylic acids, metabolism of oleic acid, and  $\omega$ -oxidation of monocarboxylic acids. Endogenous plasma concentration (20 to 80 ng/mL) and daily urinary excretion (4 to 28 mg) of azelaic acid are highly dependent on dietary intake. After topical treatment with FINEVIN™ in humans, plasma concentration and urinary excretion of azelaic acid are not significantly different from baseline levels.

### INDICATIONS AND USAGE

FINEVIN™ is indicated for the topical treatment of mild-to-moderate inflammatory acne vulgaris.

### CONTRAINDICATIONS

FINEVIN™ is contraindicated in individuals who have shown hypersensitivity to any of its components.

### WARNINGS

FINEVIN™ is for dermatologic use only and not for ophthalmic use.

There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexions, these patients should be monitored for early signs of hypopigmentation.

### PRECAUTIONS

**General:** If sensitivity or severe irritation develop with the use of FINEVIN™ treatment should be discontinued and appropriate therapy instituted.

**Information for patients:** Patients should be told:

1. To use FINEVIN™ for the full prescribed treatment period.
2. To avoid the use of occlusive dressings or wrappings.
3. To keep FINEVIN™ away from the mouth, eyes and other mucous membranes. If it does come in contact with the eyes, they should wash their eyes with large amounts of water and consult a physician if eye irritation persists.
4. If they have dark complexions, to report abnormal changes in skin color to their physician.
5. Due in part to the low pH of azelaic acid, temporary skin irritation (pruritus, burning, or stinging) may occur when FINEVIN™ is applied to broken or inflamed skin, usually at the start of treatment. However this irritation commonly subsides if treatment is continued. If it continues, FINEVIN™ should be applied only once-a-day, or the treatment should be stopped until these effects have subsided. If troublesome irritation persists, use should be discontinued, and patients should consult their physician. (See **ADVERSE REACTIONS**)

**Carcinogenesis, mutagenesis, impairment of fertility:** Azelaic acid is a human dietary component of a simple molecular structure that does not suggest carcinogenic potential, and it does not belong to a class of drugs for which there is a concern about carcinogenicity. Therefore, animal studies to evaluate carcinogenic potential with FINEVIN™ Cream were not deemed necessary. In a battery of tests (Ames assay, HGPRT test in Chinese hamster ovary cells, human lymphocyte test, dominant lethal assay in mice), azelaic acid was found to be nonmutagenic. Animal studies have shown no adverse effects on fertility.

**Pregnancy: Teratogenic Effects: Pregnancy Category B.**

Embryotoxic effects were observed in Segment I and Segment II oral studies with rats receiving 2500 mg/kg/day of azelaic acid. Similar effects were observed in Segment II studies in rabbits given 150 to 500 mg/kg/day and in monkeys given 500 mg/kg/day. The doses at which these effects were noted were all within toxic dose ranges for the dams. No teratogenic effects were observed. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human, this drug should be used during pregnancy only if clearly needed.

**Nursing Mothers:**

Equilibrium dialysis was used to assess human milk partitioning *in vitro*. At an azelaic acid concentration of 25 µg/ml, the milk/plasma distribution coefficient was 0.7 and the milk/buffer distribution was 1.0, indicating that passage of drug into maternal milk may occur. Since less than 4% of a topically applied dose is systemically absorbed, the uptake of azelaic acid into maternal milk is not expected to cause a significant change from baseline azelaic acid levels in the milk. However, caution should be exercised when FINEVIN™ is administered to a nursing mother.

**Pediatric use:**

Safety and effectiveness in pediatric patients under 12 years of age have not been established.

**ADVERSE REACTIONS**

During U.S. clinical trials with FINEVIN™ adverse reactions were generally mild and transient in nature. The most common adverse reactions occurring in approximately 1-5% of patients were pruritus, burning, stinging and tingling. Other adverse reactions such as erythema, dryness, rash, peeling, irritation, dermatitis, and contact dermatitis were reported in less than 1% of subjects. There is the potential for experiencing allergic reactions with use of FINEVIN™.

In patients using azelaic acid formulations, the following additional adverse experiences have been reported rarely: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis, reddening (signs of keratosis pilaris), and exacerbation of recurrent herpes labialis.

**DOSE AND ADMINISTRATION**

After the skin is thoroughly washed and patted dry, a thin film of FINEVIN™ should be gently but thoroughly massaged into the affected areas twice daily, in the morning and evening. The hands should be washed following application. The duration of use of FINEVIN™ can vary from person to person and depends on the severity of the acne. Improvement of the condition occurs in the majority of patients with inflammatory lesions within four weeks.

**HOW SUPPLIED**

FINEVIN™ is supplied in collapsible tubes in the following sizes:

30 g – NDC 50419-820-01

**Note:** Protect from freezing. Store between 15° – 30° C (59° – 86° F).

Distributed under license; U.S. Patent No. 4,386,104

2075562


Distributed by:

**BERLEX** Laboratories, Wayne NJ 07470

Revised July 2000

Made in Italy

6072800



**BERLEX**

**Approved Masterstat**

Component # SAG 2075489  
 US 1400100

Date: 7/25/00

Issued by: N. THOMPSON

**Package Design and  
 Development Department**  
 Berlex Laboratories  
 300 Fairfield Road, Wayne, NJ 07470  
 Phone # (973) 305-5116  
 Fax# (973) 305-5498

**BERLEX LABORATORIES**

PD&D

DRA

**PHARMA VERPACKUNGSWESEN**

Stoff-Nr.:

Datum:

Urtext-Nr.:

Farbe:

Genehmigt:



PZ1310A 22 x 22 x 92

**BERLEX**  
**Approved Masterstat**  
 Component # SAG 2075406  
 US 7034200  
 Date: 7/25/00  
 Issued by: N. THOMPSON  
**Package Design and  
 Development Department**  
 Berlex Laboratories  
 300 Fairfield Road, Wayne, NJ 07470  
 Phone # (973) 305-5116  
 Fax# (973) 305-5498

<b>BERLEX LABORATORIES</b>	
PD&D	
DRA	
<b>PHARMA VERPACKUNGSWESEN</b>	
Stoff-Nr.:	Datum:
Urtext-Nr.:	
Farbe:	
Genehmigt:	



**Active Ingredient:** Each gram of FINEVIN™ contains azelaic acid. . . . . 0.2 gm (20% w/w).

**Inactive Ingredients:** Cetyl octanoate, glycerin, glyceryl stearate and cetyl palmitate and cocoglycerides, PEG-5 glyceryl stearate, propylene glycol and purified water. Benzoic acid is present as a preservative.

**DOSAGE:** After the skin is thoroughly washed and patted dry, a thin film of FINEVIN™ cream should be gently but thoroughly massaged into the affected areas twice daily, in the morning and evening. The hands should be washed following application. Refer to accompanying literature for complete prescribing information.

**Distributed under license; U.S. Patent No. 4,386,104.**


**NOTE: Protect from freezing. Store between 15° - 30°C (59° - 86°F).**

Keep this and all drugs out of the reach of children.

**BERLEX LABORATORIES**  
Wayne, NJ 07470

7034300 US

3 N



50419-820-01

1

For Dermatologic Use Only / Not for Ophthalmic Use

2075240

R<sub>x</sub> Only

**FINEVIN™**  
(azelaic acid cream) 20%

NDC 50419-820-01  
BERLEX

**FINEVIN™**  
(azelaic acid cream) 20%

NDC 50419-820-01  
BERLEX

**FINEVIN™**  
(azelaic acid cream) 20%

24

24